By any measure, global innovation is accelerating at a dizzying pace. R&D spending, global patent applications, venture capital investment volume, and the pace of technology M&A all reflect the increase in activity.
As part of the CPhI webinar series, CAS and IQVIA join forces to deliver insights into optimizing Artificial Intelligence and Machine Learning for predictive analytics, clinical trials and drug discovery in response to COVID-19.
iuvo BioScience, a contract research organization based in Rush, NY, provides comprehensive research services for pharmaceutical and medical devices companies worldwide. iuvo teamed up with CAS IP Services SM to help clients move new products from research to release faster and at a lower cost.
This open source dataset contains over 290K structure-activity relationship (SAR) data directed at COVID-19 protein, virus and disease targets reported in the literature, patents, and other public sources for over 9K of the substances included in the CAS COVID-19 Antiviral Candidate Compounds Dataset.
The CAS Covid-19 dataset has been extracted from the CAS REGISTRY® including known anti-viral drugs and related chemical compounds that are structurally similar to known antivirals and is subject to these license terms.
Are you just getting started or ramping up machine learning for chemical and materials research? In this webinar, the panelists will discuss how to prepare for a new informatics project by exploring how to build useful data sets, identify missing capabilities, and communicate expectations.
CAS has completed a project with The National Institute of Industrial Property (INPI) of Brazil for an enhanced examination workflow solution for chemistry patent applications using a unique blend of technology, artificial intelligence, data, and expertise. The new solution reduced application examination times by up to 50%, and helped to reduce their multi-year application backlog.